Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Rafarma Pharmaceuticals, Inc. RAFA OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
51/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Rafarma Pharmaceuticals, Inc. (RAFA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.07. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Financials: revenue is $9M, -37.2%/yr average growth. Net income is $266,000, growing at -51.4%/yr. Net profit margin is 2.9% (thin). Gross margin is 7.4% (-27.8 pp trend).

Balance sheet: total debt is $0 against $10M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.13 (adequate). Debt-to-assets is 0%. Total assets: $12M.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 0/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

RAFA SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RAFA

✓
VALUE Pass
75/100
RAFA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
RAFA: -37.2%/yr revenue is, -51.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
RAFA: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet RAFA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.13 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
30/100
RAFA: Net profit margin is 2.9%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.004-0.15
Volume25K
Avg Volume (30D)22.82K
Market Cap$5.7M
Beta (1Y)0.54
Share Statistics
EPS (TTM)0.00
Shares Outstanding$87.77M
IPO Date2012-12-11
CEOSergey Brusnitsin
Financial Highlights & Ratios
Revenue (TTM)$9.08M
Gross Profit$674K
EBITDA$342K
Net Income$266K
Operating Income$405K
Total Cash$77K
Net Debt$-77K
Total Assets$12.03M
Price / Earnings (P/E)21.7
Price / Sales (P/S)0.63
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS75062C1009

Price Chart

Track all markets on TradingView
RAFA
Rafarma Pharmaceuticals, Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.15

People Also View

SNWV
SNWV
SANUWAVE Health, Inc.
$18.27
+4.34%
 APHD
APHD
Apogee 21 Holdings, Inc.
$0.87
-0.02%
 PRED
PRED
Predictive Technology Group, Inc.
$0.00
+0.00%
 BRYN
BRYN
Bryn Resources Inc.
$0.00
+0.00%
 PRKI
PRKI
Perk International Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message